IRD

Opus Genetics

• Benzinga·6d ago

  Top 3 Health Care Stocks That May Rocket Higher In July

• TipRanks·07/10 11:50

  Analysts Offer Insights on Healthcare Companies: Forte Biosciences (FBRX), Sarepta Therapeutics (SRPT) and Opus Genetics (IRD)

• TipRanks·07/10 11:36

  Cantor Fitzgerald Reaffirms Their Buy Rating on Opus Genetics (IRD)

• TipRanks·07/09 14:55

  Opus Genetics: Buy Rating Reiterated as Analyst Sees Pivotal OPGx-BEST1 Data as Key Catalyst; $10 Price Target Unchanged

• TipRanks·07/09 13:10

  Opus Genetics sets September timeline for retinal disease trial data

• Benzinga·07/09 11:06

  Opus Genetics Expects To Announce Three-month Topline Data From Cohort 1 Of Phase 1/2 Trial Of OPGx-BEST1 For Best Vitelliform Macular Dystrophy Or Autosomal-recessive Bestrophinopath, During The Second Week Of September 2026

• Reuters·07/09 11:02

  OPUS GENETICS - TO ANNOUNCE OPGX-BEST1 THREE-MONTH TOPLINE DATA FROM COHORT 1 IN SEPTEMBER 2026

• PUBT·07/09 11:01

  Opus Genetics to release 3-month Cohort 1 topline data for OPGx-BEST1 trial in September 2026

• TipRanks·07/08 13:50

  Analysts Are Bullish on Top Healthcare Stocks: Tenet Healthcare (THC), Opus Genetics (IRD)

• TipRanks·07/07 10:01

  Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Opus Genetics (IRD) and Vertex Pharmaceuticals (VRTX)

• TipRanks·07/07 08:25

  Yun Zhong Reiterates Buy on Opus Genetics as FDA-Backed, High-Power Phase 3 Design for OPGx-LCA5 Accelerates Path to Approval and Validates Broader Retinal Disease Pipeline

• TipRanks·07/06 20:40

  Analysts Are Bullish on These Healthcare Stocks: CVRx (CVRX), Opus Genetics (IRD)

• Dow Jones·07/06 17:36

  Opus Genetics Price Target Maintained With a $13.00/Share by Chardan Capital

• Dow Jones·07/06 17:36

  Opus Genetics Is Maintained at Buy by Chardan Capital

• TipRanks·07/06 17:15

  Opus Genetics: FDA-Backed Phase 3 Path and Strong Early Efficacy Support Reiterated Buy on IRD with Unchanged $10 Price Target